AlphaCentric Advisors’s AbbVie ABBV Stock Holding History

AlphaCentric Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$771K	Buy	3,544 +565	+19%	+$125K	0.77%	32
2025 Q4	$681K	Buy	+2,979	New	+$679K	0.68%	40
2024 Q4	$2.31M	Buy	+13,018	New	+$2.39M	2.31%	5
2023 Q2	–	Sell	-1,679	Closed	-$268K	–	233
2023 Q1	$268K	Sell	1,679 -14	-0.8%	-$2.14K	0.18%	116
2022 Q4	$274K	Buy	1,693 +358	+27%	+$54.9K	0.27%	109
2022 Q3	$179K	Buy	+1,335	New	+$192K	0.18%	123
2021 Q3	–	Sell	-425	Closed	-$48K	–	195
2021 Q2	$48K	Hold	425	–	–	0.01%	201
2021 Q1	$46K	Hold	425	–	–	0.02%	193
2020 Q4	$46K	Hold	425	–	–	0.02%	185
2020 Q3	$37K	Hold	425	–	–	0.02%	124
2020 Q2	$42K	Buy	+425	New	+$37.4K	0.02%	92

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaCentric Advisors's ABBV Position: Q1 2026 in Review

AlphaCentric Advisors increased its AbbVie (ABBV) stake by 19% in Q1 2026, buying an estimated $125K and bringing the position to 3,544 shares worth $771K. The position accounts for 0.77% of the portfolio, ranked #32.

AlphaCentric Advisors first reported a position in ABBV in Q2 2020 and has held it in 11 quarters since. The position peaked at $2.31M in Q4 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

AlphaCentric Advisors held 3,544 shares of AbbVie worth $771K as of Q1 2026.
AlphaCentric Advisors bought 565 AbbVie shares in Q1 2026, an estimated $125K.
AbbVie made up 0.77% of AlphaCentric Advisors's portfolio in Q1 2026, its #32 holding.
AlphaCentric Advisors first reported a position in AbbVie in Q2 2020 and has held it in 11 quarters since.
AlphaCentric Advisors's AbbVie position peaked at $2.31M in Q4 2024.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.